Technical Analysis for CU6 - Clarity Pharmaceuticals Ltd

Grade Last Price % Change Price Change
A 6.130 10.05% 0.560
CU6 closed up 10.05 percent on Friday, July 12, 2024, on 1.59 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
New 52 Week Closing High Bullish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
New 52 Week High Strength 0.00%
Stochastic Reached Overbought Strength 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%

   Recent Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product is SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Imaging Clinical Medicine Cancers Medicinal Radiochemistry Prostate Cancer Radiopharmaceuticals Treatment Of Cancer Personalized Medicine

Is CU6 a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.17
52 Week Low 0.855
Average Volume 1,455,825
200-Day Moving Average 2.675
50-Day Moving Average 4.736
20-Day Moving Average 5.147
10-Day Moving Average 5.261
Average True Range 0.312
RSI (14) 71.99
ADX 36.68
+DI 42.064
-DI 13.111
Chandelier Exit (Long, 3 ATRs) 5.234
Chandelier Exit (Short, 3 ATRs) 5.236
Upper Bollinger Bands 5.770
Lower Bollinger Band 4.523
Percent B (%b) 1.29
BandWidth 24.246
MACD Line 0.225
MACD Signal Line 0.182
MACD Histogram 0.0428
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.865
Resistance 3 (R3) 6.797 6.483 6.743
Resistance 2 (R2) 6.483 6.296 6.518 6.702
Resistance 1 (R1) 6.307 6.181 6.395 6.375 6.661
Pivot Point 5.993 5.993 6.038 6.028 5.993
Support 1 (S1) 5.817 5.806 5.905 5.885 5.599
Support 2 (S2) 5.503 5.691 5.538 5.558
Support 3 (S3) 5.327 5.503 5.518
Support 4 (S4) 5.395